BIBLIO is the largest independent book marketplace in the world, with over 100 million books.

Skip to content

Hepatitis B and D Protocols

Hepatitis B and D Protocols

Hepatitis B and D Protocols
Stock photo: cover may vary

Hepatitis B and D Protocols Hardback -

by Robert K. Hamatake (Editor); Johnson Y. Lau (Editor)

Add to wish list
  • New
  • Hardback
New

Description

Humana Press , pp. 600 1st Edition . Hardback. New.
Ask the seller a question Add to wish list
A$369.89
A$5.72 Delivery within USA
Standard delivery: 9 to 14 days
More delivery options
Ships from Cold Books (New York, United States)
The BIBLIO Guarantee

Details

  • Title Hepatitis B and D Protocols
  • Author Robert K. Hamatake (Editor); Johnson Y. Lau (Editor)
  • Binding Hardback
  • Edition U. S. EDITION
  • Condition New
  • Pages 572
  • Volumes 1
  • Language ENG
  • Publisher Humana Press
  • Publication date pp. 600 1st Edition
  • Illustrated Yes
  • Features Bibliography, Illustrated, Index
  • Bookseller's Inventory # 6286255
  • ISBN 9781588291080 / 1588291081
  • Weight 2.04 lbs (0.93 kg)
  • Dimensions 9.24 x 6.14 x 1.28 in (23.47 x 15.60 x 3.25 cm)
  • Category Medical / Nursing
  • Library of Congress subjects Delta-associated agent, Delta infection
  • Library of Congress Catalogue Number 2003011624
  • Dewey Decimal Code 616.362
  • Quantity available 4

About Cold Books New York, United States

Biblio member since 2012

Terms of Sale: 30 day return guarantee, with full refund including shipping costs for up to 30 days after delivery if an item arrives misdescribed or damaged.

Browse books from Cold Books

Reader reviews for Hepatitis B and D Protocols

Write a review for this book

There are no reviews for this book yet. Be the first to write a review!

Your review will be anonymous unless you login or create an account first.

Overall rating
Remember: You’re rating the book as a work, not the seller or the condition of the specific copy you purchased!

Important Terms and Guidelines

  • Please focus on the book’s content and context. Also, add any personal comments as to how you enjoyed the book. Substantiate your likes and dislikes. You may make comparisons to other books.
  • Reviews must be at least 140 characters in length.
  • Please do not reveal critical plot elements.
  • This is not a help line. Contact customer support if you need help.
Your review must not include:
  • Obscenities, discriminatory language, or other insulting language not suitable for public domain
  • Advertisements, “spam” content, or references to other products, offers or websites.
  • Email addresses, URLs, phone numbers, physical addresses or other contact information.
  • Overly critical comments about other reviews or reviewers
  • Time-sensitive material (i.e. promotional tours, seminars, lectures, etc.)
  • Availability, price, or alternative ordering/shipping information

From the publisher

Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g., hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.

First line

The duck hepatitis B virus (DHBV) is a species-specific virus that causes either transient (acute) or persistent infections, primarily in hepatocytes in the liver, with release of high titers of infectious virions and noninfectious "empty" surface antigen particles into the bloodstream.

From the rear cover

Despite the availability of an effective vaccine, there are still 400 million people worldwide who are chronically infected with the hepatitis B and D viruses (HBV and HDV), and more work still needs to be done in all of the key areas of managing the disease. In Hepatitis B and D Protocols, leading investigators and clinicians have joined forces to create a broad-ranging collection of cutting-edge techniques for the study of HBV and HDV infections and for the development of therapies to treat them. In this second of two volumes, Immunology, Model Systems, and Clinical Studies, the authors focus on protocols for the study of host immune responses to infection, in vitro and in vivo models of infection, and the development of antivirals. Each fully tested protocol is described in step-by-step detail by an established expert in the field and includes a background introduction outlining the principle underlying the technique, equipment and reagent lists, and tips on troubleshooting and avoiding known pitfalls. An accompanying first volume, Detection, Genotypes, and Characterization, contains user-friendly protocols for the identification and quantification of viral markers, the detection and impact of viral variants, and the study of the viral life cycle.
Taken together, Hepatitis B and D Protocols, Volume 1: Detection, Genotypes, and Characterization and Volume 2: Immunology, Model Systems, and Clinical Studies offer both new and experienced investigators an encyclopedic collection of powerful tools for studying HBV and HDV infections, as well as an essential resource for finding new therapies to treat chronically infected patients.

Please wait a moment while we load the requested page.

tracking-